Latest news : Valeo Pharma Inc.

05/02/25	Xediton Pharmaceuticals Inc. completed the acquisition of Valeo Pharma Inc. (OTCPK:VPHI.F).	CI
17/01/25	Xediton Pharmaceuticals Inc. entered into a definitive agreement to acquire Valeo Pharma Inc. (OTCPK:VPHI.F).	CI
29/01/24	Valeo Pharma Inc. Auditor Raises 'Going Concern' Doubt	CI

More news

Press Releases: Valeo Pharma Inc.

07-10	WEPP Relief Available In RVO Context, Commercial List Finds For The First Time In Ontario	AQ
07/02/25	Valeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc.	AQ
05/01/22	VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION	PR
03/11/21	Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta	PR
13/10/21	Valeo Pharma : C O R R E C T I O N from Source -- Valeo Pharma inc./	PR

More press releases

Managers and Directors: Valeo Pharma Inc.

Manager	Title	Age	Since
Pascal Tougas DFI	Director of Finance/CFO	-	20/11/2023
Nelly Komari CTO	Chief Tech/Sci/R&D Officer	-	01/06/2021
Frédéric Dumais IRC	Investor Relations Contact	-	01/06/2019

Director	Title	Age	Since
Steven Saviuk CHM	Chairman	67	06/08/2024
Richard MacKay CHM	Chairman	91	25/07/2018
Marc Léger BRD	Director/Board Member	67	27/04/2022

More insiders

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets 18:42:53 15/07/2026 +04			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-99.00%

Market Cap	6.24M 4.52M 3.87M 3.6M 3.32M 433M 6.34M 42.59M 16.65M 217M 16.96M 16.59M 714M	P/E 2022	-2.09x	P/E 2023	-0.45x
Enterprise Value	64.5M 46.68M 40M 37.19M 34.33M 4.47B 65.59M 440M 172M 2.24B 175M 172M 7.38B	EV / Sales 2022	3.37x	EV / Sales 2023	1.35x
Free-Float	52.66%	Yield 2022 *	-	Yield 2023	-

Current year	0		0
1 year	0		0
3 years	0		0.25
5 years	0		0.84
10 years	0		1.4

Date	Insider	Type	Main position	% Market Cap.
11/11/24	Frédéric Dumais	Other	Investor Relations Manager	0%
11/11/24	Frédéric Dumais	Other	Investor Relations Manager	0%
11/11/24	Frédéric Dumais	Other	Investor Relations Manager	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALEO PHARMA INC.	-.--%	-.--%	-	-	98
ELI LILLY AND COMPANY	+4.46%	+5.38%	+83.42%	+134.31%	1,093B
JOHNSON & JOHNSON	+0.85%	+5.24%	+55.13%	+58.51%	653B
ABBVIE INC.	+2.72%	+6.35%	+28.76%	+77.15%	458B
ROCHE HOLDING AG	+1.80%	-0.41%	+43.52%	+44.05%	355B
NOVARTIS AG	+1.24%	+1.00%	+26.84%	+42.21%	294B
ASTRAZENECA PLC	+2.07%	+1.74%	+2.66%	+13.06%	248B
AMGEN INC.	+4.02%	+6.77%	+51.17%	+68.96%	230B
NOVO NORDISK A/S	+1.05%	-2.52%	-13.83%	-52.13%	203B
GILEAD SCIENCES, INC.	+2.90%	+8.71%	+25.10%	+94.52%	178B
Average	+1.65%	+1.08%	+33.64%	+53.40%	371.05B
Weighted average by Cap.	+1.31%	+1.45%	+47.89%	+73.74%

Valeo Pharma Inc. Stock

Stocks

VPHIF

CA91915B1085

Pharmaceuticals

Valuation: Valeo Pharma Inc.

Chart: Valeo Pharma Inc.

Latest news : Valeo Pharma Inc.

Press Releases: Valeo Pharma Inc.

Course Extremes

Managers and Directors: Valeo Pharma Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

	2022	2023
Net sales	27.74M 20.08M 17.21M 16M 14.77M 1.92B 28.21M 189M 74.05M 965M 75.45M 73.81M 3.18B	53.91M 39.02M 33.44M 31.08M 28.7M 3.74B 54.82M 368M 144M 1.88B 147M 143M 6.17B
Net income	-25.75M -18.63M -15.97M -14.84M -13.71M -1.79B -26.18M -176M -68.72M -896M -70.01M -68.49M -2.95B	-27.81M -20.13M -17.25M -16.03M -14.8M -1.93B -28.28M -190M -74.22M -968M -75.62M -73.97M -3.18B
Net Debt	38.94M 28.18M 24.15M 22.45M 20.73M 2.7B 39.6M 266M 104M 1.35B 106M 104M 4.46B	58.26M 42.17M 36.13M 33.59M 31.01M 4.04B 59.24M 398M 155M 2.03B 158M 155M 6.67B